CROWN

NCT03052608 📎

Regimen

Experimental
lorlatinib
Control
crizotinib

Population

ALK+ advanced NSCLC 1L

Key finding

mPFS NR vs 9.3 mo, HR 0.28 (0.19-0.41); intracranial response 82% vs 23%

Source: PMID 33207094

Timeline

  • Enrollment start: 2017-04-27 📎

Guideline citations

  • NCCN NSCLC Version 5.2026 (p.208)
  • CSCO NSCLC 2025 ⚠️ OCR source